WO1996029330A1 - Derives de la thiazole - Google Patents
Derives de la thiazole Download PDFInfo
- Publication number
- WO1996029330A1 WO1996029330A1 PCT/JP1996/000763 JP9600763W WO9629330A1 WO 1996029330 A1 WO1996029330 A1 WO 1996029330A1 JP 9600763 W JP9600763 W JP 9600763W WO 9629330 A1 WO9629330 A1 WO 9629330A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- atom
- formula
- substituted
- Prior art date
Links
- 150000007979 thiazole derivatives Chemical class 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 96
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 48
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 41
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 21
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 103
- -1 R 4 forces Chemical group 0.000 claims description 86
- 125000003545 alkoxy group Chemical group 0.000 claims description 33
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 125000004434 sulfur atom Chemical group 0.000 claims description 17
- 125000003277 amino group Chemical group 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 3
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 26
- 229960003638 dopamine Drugs 0.000 abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 9
- 208000018300 basal ganglia disease Diseases 0.000 abstract description 7
- 239000002464 receptor antagonist Substances 0.000 abstract description 5
- 229940044551 receptor antagonist Drugs 0.000 abstract description 5
- 230000000561 anti-psychotic effect Effects 0.000 abstract description 4
- 208000027776 Extrapyramidal disease Diseases 0.000 abstract description 2
- 239000001257 hydrogen Substances 0.000 abstract description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 123
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 111
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 87
- 239000000243 solution Substances 0.000 description 78
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 72
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 64
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 50
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 46
- 239000002904 solvent Substances 0.000 description 46
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 37
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 34
- 239000000203 mixture Substances 0.000 description 34
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- 239000002274 desiccant Substances 0.000 description 32
- 230000015572 biosynthetic process Effects 0.000 description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 25
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000012044 organic layer Substances 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- 235000011054 acetic acid Nutrition 0.000 description 22
- 150000002367 halogens Chemical class 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 238000003818 flash chromatography Methods 0.000 description 20
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 19
- 238000001914 filtration Methods 0.000 description 19
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 18
- 239000012442 inert solvent Substances 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 239000002253 acid Substances 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 230000000704 physical effect Effects 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- 150000001298 alcohols Chemical class 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 238000009739 binding Methods 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- 150000002170 ethers Chemical class 0.000 description 11
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 229930195733 hydrocarbon Natural products 0.000 description 11
- 150000002430 hydrocarbons Chemical class 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000008279 sol Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 150000007524 organic acids Chemical class 0.000 description 9
- 235000010724 Wisteria floribunda Nutrition 0.000 description 8
- 238000010511 deprotection reaction Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- 239000012046 mixed solvent Substances 0.000 description 8
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 235000005985 organic acids Nutrition 0.000 description 7
- 150000002896 organic halogen compounds Chemical class 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 201000000980 schizophrenia Diseases 0.000 description 7
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 150000001735 carboxylic acids Chemical class 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 150000007529 inorganic bases Chemical class 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 102000015554 Dopamine receptor Human genes 0.000 description 5
- 108050004812 Dopamine receptor Proteins 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 229960004170 clozapine Drugs 0.000 description 5
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 3
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 125000005999 2-bromoethyl group Chemical group 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000012351 deprotecting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 230000002140 halogenating effect Effects 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 3
- 229950001675 spiperone Drugs 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 150000003556 thioamides Chemical class 0.000 description 3
- 150000003585 thioureas Chemical class 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 150000003672 ureas Chemical class 0.000 description 3
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- PDMRZBDGWLIEGF-UHFFFAOYSA-N 1,3-thiazole dihydrobromide Chemical compound Br.Br.c1cscn1 PDMRZBDGWLIEGF-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- KFZRCYSFVZGGGW-UHFFFAOYSA-N 1-bromo-3-(2-ethoxyethoxy)propane Chemical compound CCOCCOCCCBr KFZRCYSFVZGGGW-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 2
- ALVRAPXLHVZNHU-UHFFFAOYSA-N 4-[(4-fluorophenyl)methylidene]piperidine;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C=C1CCNCC1 ALVRAPXLHVZNHU-UHFFFAOYSA-N 0.000 description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
- HXAOUYGZEOZTJO-UHFFFAOYSA-N 4-chloro-1-(4-fluorophenyl)butan-1-one Chemical compound FC1=CC=C(C(=O)CCCCl)C=C1 HXAOUYGZEOZTJO-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- 101100274581 Caenorhabditis elegans chc-1 gene Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 2
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 2
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N methyl phenyl ether Natural products COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical group FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- WTRWBYGUMQEFFI-UHFFFAOYSA-N (4-fluorophenyl)(pyridin-4-yl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)C1=CC=NC=C1 WTRWBYGUMQEFFI-UHFFFAOYSA-N 0.000 description 1
- ABERUOJGWHYBJL-UHFFFAOYSA-N (4-fluorophenyl)-piperidin-4-ylmethanone Chemical compound C1=CC(F)=CC=C1C(=O)C1CCNCC1 ABERUOJGWHYBJL-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- ZYVPOPWDOQZIQC-UHFFFAOYSA-N 1,3-thiazole;dihydrochloride Chemical compound Cl.Cl.C1=CSC=N1 ZYVPOPWDOQZIQC-UHFFFAOYSA-N 0.000 description 1
- DDGHBOLOCQWPKE-UHFFFAOYSA-N 1,3-thiazole;hydrobromide Chemical compound [Br-].C1=CSC=[NH+]1 DDGHBOLOCQWPKE-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- DOYNJLSWPZMUDN-UHFFFAOYSA-N 2,4,5-triethyl-1,3-thiazole Chemical compound CCC1=NC(CC)=C(CC)S1 DOYNJLSWPZMUDN-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- KYUGCPXEZSVXBJ-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-thiazole hydrochloride Chemical compound Cl.FC1=CC=C(C=C1)C=1SC=CN1 KYUGCPXEZSVXBJ-UHFFFAOYSA-N 0.000 description 1
- HLEPWSHQXFPJSP-UHFFFAOYSA-N 2-(oxomethylidene)piperidin-4-one Chemical compound O=C=C1CC(=O)CCN1 HLEPWSHQXFPJSP-UHFFFAOYSA-N 0.000 description 1
- CGZDWVZMOMDGBN-UHFFFAOYSA-N 2-Ethylthiazole Chemical compound CCC1=NC=CS1 CGZDWVZMOMDGBN-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- WAOQONBSWFLFPE-VIFPVBQESA-N 3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1OC WAOQONBSWFLFPE-VIFPVBQESA-N 0.000 description 1
- NPWCKOSVOWSDJA-UHFFFAOYSA-N 3-(6-fluoro-1,2-benzothiazol-3-yl)propyl acetate Chemical compound FC1=CC=C2C(CCCOC(=O)C)=NSC2=C1 NPWCKOSVOWSDJA-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KOAMXHRRVFDWRQ-UHFFFAOYSA-N 4,4-dimethyl-5h-1,3-oxazole Chemical compound CC1(C)COC=N1 KOAMXHRRVFDWRQ-UHFFFAOYSA-N 0.000 description 1
- HBGFNKPQIVCREN-UHFFFAOYSA-N 4-fluoro-2-methylthiobenzaldehyde Chemical compound CC1=CC(F)=CC=C1C=S HBGFNKPQIVCREN-UHFFFAOYSA-N 0.000 description 1
- WERIZXWRRZOCLX-UHFFFAOYSA-N 4-fluoro-2-methylthiophene Chemical compound CC1=CC(F)=CS1 WERIZXWRRZOCLX-UHFFFAOYSA-N 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- KXCQDIWJQBSUJF-UHFFFAOYSA-N 4-phenyl-1,3-thiazole Chemical compound S1C=NC(C=2C=CC=CC=2)=C1 KXCQDIWJQBSUJF-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- LCGSQJGWSWKEAW-UHFFFAOYSA-N 5-(2-chloroethyl)-4-(4-fluorophenyl)-1,3-thiazol-2-amine;hydrobromide Chemical compound Br.S1C(N)=NC(C=2C=CC(F)=CC=2)=C1CCCl LCGSQJGWSWKEAW-UHFFFAOYSA-N 0.000 description 1
- XYBXLLYHWOOZBD-UHFFFAOYSA-N 5-(2-chloroethyl)-4-(4-fluorophenyl)-1,3-thiazole;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C1=C(CCCl)SC=N1 XYBXLLYHWOOZBD-UHFFFAOYSA-N 0.000 description 1
- NDCDTEAVJLFFBR-UHFFFAOYSA-N 5-(2-chloroethyl)-4-phenyl-1,3-thiazol-2-amine;hydron;bromide Chemical compound Br.S1C(N)=NC(C=2C=CC=CC=2)=C1CCCl NDCDTEAVJLFFBR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000689227 Cora <basidiomycete fungus> Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920001393 Crofelemer Polymers 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 241001192649 Larosterna inca Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 101100062121 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cyc-1 gene Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004234 Yellow 2G Substances 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- GGISZLOBBISXOZ-UHFFFAOYSA-N acetic acid;chloroform Chemical compound CC(O)=O.ClC(Cl)Cl GGISZLOBBISXOZ-UHFFFAOYSA-N 0.000 description 1
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
- PHENPABYBHPABM-UHFFFAOYSA-N acetic acid;octane Chemical compound CC(O)=O.CCCCCCCC PHENPABYBHPABM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001340 alkali metals Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 125000005002 aryl methyl group Chemical group 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical class C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical group [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 1
- 235000019126 equol Nutrition 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- KKHGTBOTLAEWSS-UHFFFAOYSA-N ethyl 3-[2-(4-fluorophenyl)-2-oxoethyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OCC)CCC1CC(=O)C1=CC=C(F)C=C1 KKHGTBOTLAEWSS-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 150000004689 octahydrates Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical class O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to a thiazole derivative having an antipsychotic effect.
- Antipsychotics are also used in the treatment of schizophrenia and in the treatment of cerebrovascular disorders and problematic behaviors in senile dementia (aggression, mental excitement, wandering, delirium, etc.). While with mosquitoes, dopamine D 2 receptor antagonist is a conventional antipsychotic, extrapyramidal disorders has become a strong, large problem is a side effect.
- dopamine D 4 receptor antagonists unlike dopamine D 2 receptor antagonists, are very likely to be novel schizophrenia treatments without the extra-pyramidal side effect (Nature, 350, 610). -614 (1991); Nature, 358, 109 (1992); Nature, 365, 393 (1993); Nature, 365, 441-445 (1993)).
- Clozapine is an example of this type of ⁇ f dangling compound. Affinity for dopamine ⁇ receptors clozapine it has been reported to be higher than the affinity for de one dopamine D 2 receptor (Nature, 350, 610-614 (1991 )). Furthermore, in clinical trials of clozapine, unlike dopamine D 2 receptor antagonist, it is effective in schizophrenia and negative symptoms of drug resistance, is that force ⁇ reported less extrapyramidal disorder (Arch. Gen Psych., 4 ⁇ , 789-796 (1988)). However, clozapine is a major drawback due to the blood disorder called agranulocytosis and deaths reported (Summary and Clinical Data. Sandoz, Canada Inc. (1990)).
- dopamine D 4 receptor antagonists without such side effects, a high usefulness as therapeutic agents, such as potential force 'very low schizophrenia cause extrapyramidal disorders Disclosure of the stomach c invention
- An object of the present invention is to provide a dopamine D 4 receptor antagonist compounds having antipsychotic activity without causing extrapyramidal disorders.
- the present inventors have conducted intensive studies on thiazole derivatives, and as a result, have found a novel thiazole derivative exhibiting high affinity for dopamine receptors, and have completed the present invention. '
- the present invention includes the following inventions.
- Ar ′ represents a substituted or unsubstituted phenyl group or a phenyl group
- ⁇ 1 and ⁇ 2 are different from each other and represent a nitrogen atom or a sulfur atom
- R 1 is a hydrogen atom
- carbon atom Represents an alkyl group having 1 to 5 alkyl groups, a phenyl group, or an unsubstituted or an amino group mono- or di-substituted with an alkyl group having 1 to 5 carbon atoms
- R 2 has the formula (i):
- a represents an integer of 1 to 3
- b represents 2 or 3
- c represents an integer of 1 to 5
- Ar 2 represents a substituted or unsubstituted phenyl group or a phenyl group
- Z 1 and Z 2 are the same or different and have 1 to 5 carbon atoms. Or an oxo group or an alkylenedioxy group having 2 to 3 carbon atoms in combination.
- X ′ and X 2 are the same or different and represent a hydrogen atom, a halogen atom, an alkoxy group having 1 to 5 carbon atoms or a hydroxyl group.
- Y 3 represents N or CH
- Y 4 represents an oxygen atom, a zeo atom or NH.
- R 4 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, or a substituted or unsubstituted furyl group.
- R 5 is a hydrogen atom, a substituted or unsubstituted alkyl having 1 to 7 carbon atoms.
- Ar 1 is a fuunyl group or a phenyl group substituted with 1 or 2 arbitrarily selected from a halogen atom and an alkoxy group having 1 to 5 carbon atoms.
- Y 1 is a nitrogen atom
- Y 2 is a sulfur atom
- R ′ is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an amino group or a monoalkylamino group having 11 to 5 carbon atoms
- Ar 'and Arufaganma 2 are the same or different unsubstituted or Ri Fuweniru groups der substituted with one or two halogen atoms
- Y' There is a nitrogen atom, an Upsilon 2 force ⁇ sulfur atom
- R ' is a hydrogen atom, Ri alkyl group, amino group or monoalkylamino group der of 1 to 5 carbon atoms from 1 to 5 carbon
- Zeta 1 and Zeta 2 compounds are Okiso group jointly.
- Equation (G) (I-i-i-4):
- Ar ′ is an unsubstituted or substituted fuunyl group substituted with one or two halogen atoms
- Y 1 is a nitrogen atom
- Y 2 Is a sulfur atom is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an amino group or a monoalkylamino group having 1 to 5 carbon atoms.
- Ar 1 and ⁇ 2 are the same or different and each is a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, a hydroxyl group and a trifluoro group.
- -phenyl group or substituted from Oromechiru group with one or two arbitrarily selected is Fuweniru group, an Upsilon 1 forces a nitrogen atom, Y 2 is a sulfur atom, R 1 is a hydrogen atom, A compound which is an alkyl group having 1 to 5 carbon atoms, an amino group or a monoalkylamino group having 1 to 5 carbon atoms.
- Ar ′ and Ar 2 are the same or different and are phenyl substituted by 1 or 2 arbitrarily selected from a halogen atom and an alkoxy group having 1 to 5 carbon atoms. Or a phenyl group, Y 1 is a nitrogen atom, Y 2 is a sulfur atom, c is 2 or 3, B ′ — B 2 is CH 2 —CH, B 3 is CO And R 1 is a hydrogen atom, a methyl group, an amino group or a methylamino group.
- Ar ′ and Ar 2 may be the same or different and a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, a hydroxyl group and trifluoromethyl Fuyuniru group or substituted with 1 or 2 substituents selected from group optionally is Funiniru group, 'a force ⁇ nitrogen atom, Y 2 is Ri Oh sulfur atom, R' Y is a hydrogen atom, the number of carbon atoms A compound which is an alkyl group of 1 to 5, an amino group or a monoalkylamino group of 1 to 5 carbon atoms.
- a r 1 and A r 2 is 1 or selected from an alkoxy group a halogen atom and a carbon number from 1 to 5 optionally the same or different Phenyl group or substituted by two is phenyl group, Y 'is a nitrogen atom, a Y 2 forces sulfur atom, c is 2 or 3, R' is a hydrogen atom, a methyl group, ⁇ Mino A phenyl group or a phenyl group substituted with an R 4 group, a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, or a halogen atom.
- examples of the substituted phenyl group represented by Ar ′, Ar 2 or include a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, And a phenyl group substituted with one or two arbitrarily selected from a hydroxyl group and a trifluoromethyl group.
- Examples of the substituted alkyl group having 1 to 7 carbon atoms or the alkenyl group having 3 to 7 carbon atoms represented by R 3 include an unsubstituted or hydroxyl group, an alkoxy group having 1 to 5 carbon atoms and One or two selected from a phenyl group, a naphthyl group and an indolyl group, which is substituted with one or two selected from halogen atoms, preferably having an end-substituted alkyl group having 1 to 7 carbon atoms or An alkenyl group having 3 to 7 carbon atoms is exemplified.
- the halogen atom is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, and is preferably a fluorine atom.
- the alkyl group having 1 to 5 carbon atoms and the alkyl group having 1 to 7 carbon atoms are a linear, branched, or ⁇ ⁇ ⁇ ⁇ -shaped alkyl group or an alkyl group substituted with a ⁇ -shaped alkyl group.
- the alkenyl group having 3 to 7 carbon atoms is a linear or branched alkenyl group, for example, a 2-propene-1-yl group, a 3-methyl-2-butene-11-yl group, and the like.
- the alkynyl group having 3 to 7 carbon atoms is a linear or branched alkynyl group, such as a 2-propynyl group.
- the alkoxy group having 1 to 5 carbon atoms is a linear or branched alkoxy group, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, and t-alkoxy. Butoxy, pentoxy, 3-methylbutoxy And so on.
- the alkoxycarbonyl group having 2 to 7 carbon atoms is a linear or branched alkoxycarbonyl group, such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, and a butoxycarbonyl group.
- a methoxycarbonyl group such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, and a butoxycarbonyl group.
- Examples of the amino group mono- or di-substituted by an alkyl group having 1 to 5 carbon atoms include a methylamino group, a dimethylamino group, an ethylamino group, and a acetylamino group.
- a phenyl group substituted with one or two arbitrarily selected from a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, a hydroxyl group and a trifluoromethyl group includes, for example, 2-fluorophenyl group, 3-fluorophenyl group, 4-fluorophenyl group, 4-chlorophenyl group, 4-bromophenyl group, 2,4-difluorophenyl group, 3,4-dichlorophenyl group, 3-bromo- 4-methoxyphenyl, 4-methylphenyl, 3,4-dimethylphenyl, 4-isopropylphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 4-isopropoxy Examples thereof include an enyl group, a 4-hydroxyphenyl group, a 2-trifluoromethylphenyl group, a 3-trifluoromethylphenyl group, and a
- alkyl group having 1 to 7 carbon atoms include a benzyl group, a 4-fluorobenzene group, a 2-phenylethyl group, and a 2-phenyl group.
- alkenyl group having 3 to 7 carbon atoms examples include (2E) —3-phenyl-2-propene-1-yl group, (3E) —4-1 (4-fluorophenyl) -13-butene— A 1-yl group and a 4,4-bis (4-fluorophenyl) -13-butene-11-yl group.
- the pharmaceutically acceptable salts in the present invention include, for example, salts with mineral acids such as sulfuric acid, hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, trifluoroacetic acid, methanesulfone Salts with organic acids such as acids, pamoic acid, decanoic acid and enanthic acid.
- mineral acids such as sulfuric acid, hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, trifluoroacetic acid, methanesulfone Salts with organic acids such as acids, pamoic acid, decanoic acid and enanthic acid.
- the compound of the formula (I) may have an optically active substance due to the presence of an asymmetric carbon, and the present invention includes any of them.
- the compound of the formula (I) can be produced by the following method.
- Ar 'Ar ⁇ B' Bs R 'F ⁇ x FR 4 X 1 , X 2 , Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Z,, Z 2 , Z 3 , Z 4 , a, b, c, d and e are as defined in the above formula (I).
- M represents a hydrogen atom or an alkali metal atom such as lithium, sodium, or potassium;
- R 6 represents an alkyl group having 1 to 6 carbon atoms or a benzyl group
- R 7 represents R 3 excluding a hydrogen atom and an alkoxycarbonyl group having 2 to 7 carbon atoms
- R 8 and R s are the same or different and each represent an alkyl group having 1 to 5 carbon atoms, or (CH 2 ) z or (CH 2 ) 3 together;
- R 1 Is an alkyl group having 1 to 5 carbon atoms, an alkoxycarbonyl group having 2 to 6 carbon atoms, a benzyloxycarbonyl group, an acyl group having 2 to 7 carbon atoms, a alkane sulfonyl group having 1 to 7 carbon atoms or a toluenesulfonyl group Indicates that
- X 3 represents a chlorine atom, a bromine atom, an iodine atom, an alkane sulfonyloxy group having 1 to 7 carbon atoms or a toluenesulfonyloxy group,
- X 4 represents a bromine atom or an iodine atom
- X 5 represents a chlorine atom, a bromine atom or an iodine atom
- X 6 and X 7 are the same or different and each represent a hydrogen atom or an alkoxy group having 1 to 5 carbon atoms;
- X 8 represents hydroxyl S when X 1 represents an alkoxy group, and represents X ′ when X 1 represents other than an alkoxy group.
- X s represents a hydroxyl group to indicate X 2 force alkoxy groups, when X 2 represents a non-alkoxy group designates an X 2,
- ⁇ and ⁇ ⁇ represent the same hydroxyl group or different hydroxyl groups and hydrogen atoms
- Y 6 and Y 7 are different from each other and represent a carbonyl group or a methylene group
- the Z 5 and zeta beta together represents hydrogen atom, indicates Okiso group or methylene group jointly,
- the inert solvent is, for example, an organic carboxylic acid such as acetic acid, chloroform, Organic halogen compounds such as carbon tetrachloride, alcohols such as ethanol and isopropanol, ethers such as getyl ether, tetrahydrofuran and dioxane, hydrocarbons such as benzene and toluene, water, and a mixed solvent thereof. And so on.
- organic carboxylic acid such as acetic acid, chloroform
- Organic halogen compounds such as carbon tetrachloride
- alcohols such as ethanol and isopropanol
- ethers such as getyl ether, tetrahydrofuran and dioxane
- hydrocarbons such as benzene and toluene
- water and a mixed solvent thereof.
- Halogenating agents include chlorine, bromine, iodine, N-chlorosuccinimide, N-bromosuccinimide and the like.
- the sulfurizing agent is, for example, diphosphorus pentasulfide, Mouth-Isson's reagent and the like.
- N-alkoxycarbonyl compound (4) is halogenated in the same manner as described above and reacted with a thiourea derivative or thioamide derivative represented by the formula (2), or a urea derivative or amide derivative represented by the formula (3) is converted to a sulfurizing agent.
- the compound (5) of the present invention is obtained by reacting with the above.
- compound (6) of the present invention can be obtained by hydrolyzing compound (5) with an acid or a base in an inert solvent.
- the acid is, for example, an inorganic acid such as hydrochloric acid, hydrobromic acid, or sulfuric acid, or an organic acid such as trifluoroacetic acid
- the base is, for example, an inorganic base such as sodium hydroxide, potassium hydroxide, or barium hydroxide. It is.
- Inert solvents include, for example, organic carboxylic acids such as acids, organic halogen compounds such as chloroform and dichloromethane, and solvents such as ethanol and isopropanol.
- organic carboxylic acids such as acids
- organic halogen compounds such as chloroform and dichloromethane
- solvents such as ethanol and isopropanol.
- examples thereof include ethers such as alcohols, tetrahydrofuran and dioxane, hydrocarbons such as toluene, ketone compounds such as acetone and methyl ethyl ketone, water, and a mixed solvent thereof.
- the compound (8) of the present invention can also be obtained by reacting the NH compound (6) obtained by the above reaction with the compound (7) in an inert solvent in the presence of a base.
- the base includes, for example, organic amines such as triethylamine, diisopropylethylamine, pyridine, alcohols such as sodium ethoxide, alkali metal amides such as sodium amide, sodium hydrogen carbonate, sodium carbonate and the like. And inorganic bases such as sodium carbonate, sodium hydroxide and sodium hydride, and organic acid salts such as sodium acetate.
- organic amines such as triethylamine, diisopropylethylamine, pyridine
- alcohols such as sodium ethoxide
- alkali metal amides such as sodium amide
- sodium hydrogen carbonate sodium carbonate and the like
- inorganic bases such as sodium carbonate, sodium hydroxide and sodium hydride, and organic acid salts such as sodium acetate.
- Inert solvents include, for example, organic carboxylic acids such as acetic acid, organic halogen compounds such as chloroform, carbon tetrachloride, alcohols such as ethanol and isopropanol, and ethers such as tetrahydrofuran and dioxane; Examples include hydrocarbons such as benzene and toluene, ketone compounds such as acetone and methyl ethyl ketone, N, N-dimethylformamide, acetonitrile, water, and mixed solvents thereof.
- organic carboxylic acids such as acetic acid
- organic halogen compounds such as chloroform, carbon tetrachloride
- alcohols such as ethanol and isopropanol
- ethers such as tetrahydrofuran and dioxane
- hydrocarbons such as benzene and toluene
- ketone compounds such as acetone and methyl ethyl ketone
- the compound (11) of the present invention can be obtained by reacting the compound (10) with an acid in an inert solvent.
- the acid is, for example, an inorganic acid such as hydrochloric acid or sulfuric acid, or an organic acid such as P-toluenesulfonic acid or trifluoroacetic acid.
- Inert solvents include, for example, organic acids such as acetic acid, organic halogen compounds such as chloroform, alcohols such as methanol, ethanol, and isopropanol; ethers such as getyl ether, tetrahydrofuran, and dioxane; and toluene. Hydrocarbons, ketone compounds such as acetone and methyl ethyl ketone, N, N-dimethylformamide, acetonitrile, water or a mixture of these
- the ketone (12) is halogenated with a halogenating agent in the same manner as in Reaction Scheme 1, and reacted with a thiourea derivative or thioamide derivative represented by Formula (2), or a urea derivative or amide derivative represented by Formula (3) Is reacted with an amine derivative (14) or (15) in an inert solvent in the presence of a base to give the compound (16) of the present invention. Or (17) can be obtained.
- the base means, for example, organic amines such as triethylamine, diisopropylethylamine, pyridine, alcoholates such as sodium ethoxide, alkali metal amides such as sodium amide, sodium hydrogen carbonate, sodium carbonate and the like.
- organic bases such as carbon dioxide, sodium hydroxide and hydrogenated sodium; and organic acid salts such as sodium acetate.
- Inert solvents include, for example, organic carboxylic acids such as acids, organic halogen compounds such as chloroform, tetrachlorocarbon, alcohols such as methanol, ethanol, and isopropanol, ethers such as tetrahydrofuran and dioxane, and benzene.
- organic carboxylic acids such as acids
- organic halogen compounds such as chloroform, tetrachlorocarbon
- alcohols such as methanol, ethanol, and isopropanol
- ethers such as tetrahydrofuran and dioxane
- benzene examples include hydrocarbons such as benzene and toluene, ketone compounds such as acetone and methyl ethyl ketone, ⁇ , ⁇ -dimethylformamide, acetonitrile, water, and mixed solvents thereof.
- the compound (20) of the present invention can be obtained by reacting the compound (19) with an acid in an inert solvent.
- the acids include, for example, inorganic acids such as hydrochloric acid and sulfuric acid, and organic acids such as p-toluenesulfonic acid and trifluoroacetic acid.
- Inert solvents include, for example, organic acids such as acetic acid, organic halogen compounds such as chloroform, alcohols such as methanol, ethanol, and isopropanol; ethers such as getyl ether, tetrahydrofuran, and dioxane; and toluene. Hydrocarbons, ketone compounds such as acetone and methyl ethyl ketone,
- the inert solvent includes, for example, organic ⁇ I such as acetic acid, organic halogen compounds such as chloroform, alcohols such as ethanol and isopropanol, ethers such as ethyl ether, tetrahydrofuran, and dioxane, and toluene. And ketones such as acetone and methyl ethyl ketone, ⁇ , ⁇ -dimethylformamide, acetate, water and a mixed solvent thereof.
- organic ⁇ I such as acetic acid
- organic halogen compounds such as chloroform
- alcohols such as ethanol and isopropanol
- ethers such as ethyl ether, tetrahydrofuran, and dioxane
- ketones such as acetone and methyl ethyl ketone, ⁇ , ⁇ -dimethylformamide, acetate, water and a mixed solvent thereof.
- the 4-benzylidene biperidine derivative represented by the formula (15) is a derivative of piperidone.
- Isomer (24) and dialkyl aryl methyl phosphonet (25) or triphenyl aryl methyl phosphonium salt (26) are condensed in an inert solvent in the presence of a base to give the compound (2 After 7), the protecting group can be removed with a deprotecting agent.
- the base is sodium hydride, potassium hydride, sodium methoxide, potassium t-butoxide, n-butyllithium, lithium diisopropylamide, lithium bis (trimethylsilyl) amide, sodium amide, etc.
- the catalyst used such as 15-crown-5 ether and 18-crown-6 ether.
- the inert solvent includes, for example, ethers such as diethyl ether, tetrahydrofuran and dioxane, hydrocarbons such as benzene and toluene, and alcohols such as ethanol.
- ethers such as diethyl ether, tetrahydrofuran and dioxane
- hydrocarbons such as benzene and toluene
- alcohols such as ethanol.
- reaction solvent at the time of deprotection examples include ethers such as getyl ether, tetrahydrofuran, and dioxane; hydrocarbons such as benzene and toluene; alcohols such as ethanol; organic carboxylic acid esters such as ethyl acetate; Examples include ketones such as cetone, alkyl halides such as dichloromethane and chloroform, organic carboxylic acids such as acetic acid, N, N-dimethylformamide, water, and a mixed solvent thereof.
- ethers such as getyl ether, tetrahydrofuran, and dioxane
- hydrocarbons such as benzene and toluene
- alcohols such as ethanol
- organic carboxylic acid esters such as ethyl acetate
- ketones such as cetone, alkyl halides such as dichloromethane and chloroform
- organic carboxylic acids such as acetic acid, N, N-
- Examples of the deprotecting agent include, except when is an alkyl group having 1 to 5 carbon atoms, for example, inorganic acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid; organic acids such as trifluoroacetic acid, formic acid, and methanesulfonic acid; Acids such as a dioxane solution of hydrogen or an ethyl acetate solution, and a solution of hydrogen bromide in acetic acid; bases such as inorganic bases such as sodium hydroxide, hydroxide hydroxide, and hydroxide hydroxide; Also R '.
- inorganic acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid
- organic acids such as trifluoroacetic acid, formic acid, and methanesulfonic acid
- Acids such as a dioxane solution of hydrogen or an ethyl acetate solution, and a solution of hydrogen bromide in acetic acid
- bases such as inorganic bases
- ketone compound (28) is reacted with a Grignard reagent (29) to give a tertiary alcohol (30), followed by simultaneous or separate deprotection and dehydration to produce a synthetic intermediate (I). 3 1) can be obtained.
- R ' is used as the deprotecting agent. Except when is an alkyl group having 1 to 5 carbon atoms, for example, inorganic acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid, organic acids such as trifluoroacetic acid, formic acid, and methanesulfonic acid; a dioxane solution of hydrogen chloride or ethyl acetate Acids such as solution and hydrogen peroxide solution; bases such as inorganic bases such as sodium hydroxide, potassium hydroxide, and sodium hydroxide; When R 1 Q is an alkyl group having 1 to 5 carbon atoms, after reacting with an alkoxycarbonyl halide having 2 to 6 carbon atoms in the presence or absence of a base such as triethylamine, diisopropylamine, or potassium carbonate. Deprotection is performed with the deprotection agent.
- inorganic acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid
- organic acids such as tri
- the dehydrating agent examples include inorganic acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid; organic acids such as trifluoroacetic acid, formic acid, and methanesulfonic acid; a dioxane solution of hydrogen chloride or an ethyl acetate solution; and an acetic acid solution of hydrogen bromide. Acids.
- organic amines such as triethylamine, diisopropylethylamine, and pyridine; alcohols such as sodium ethoxide; alkali metal amides such as sodium amide; sodium hydrogen carbonate; Dehydration can also be carried out using a base such as an inorganic base such as sodium, potassium carbonate, sodium hydroxide or sodium hydride, or an organic acid salt such as sodium acetate.
- a base such as an inorganic base such as sodium, potassium carbonate, sodium hydroxide or sodium hydride, or an organic acid salt such as sodium acetate.
- Examples of the solvent for the Grignard reaction include ethers such as getyl ether, tetrahydrofuran and dioxane, and hydrocarbons such as benzene and toluene.
- Examples of the reaction solvent at the time of deprotection include ethers such as getyl ether, tetrahydrofuran, and dioxane; hydrocarbons such as benzene and toluene; alcohols such as ethanol; organic carboxylic acid esters such as ethyl acetate; Examples thereof include ketones such as cetone, alkyl halides such as dichloromethane and chloroform, organic carboxylic acids such as acetic acid, N, N-dimethylformamide, water, and a mixed solvent thereof.
- the phenol compound (34) or (35), which is the compound of the present invention, is prepared by converting the corresponding alkoxy compound (32) or (33) into an inert solvent such as hydrobromic acid or boron tribromide. It is obtained by reacting with a de-O-alkylidene.
- the inert solvent includes hydrocarbons such as benzene and toluene, alkyl halides such as dichloromethane and chloroform, alcohols such as ethanol, organic carboxylic acids such as acetic acid, water, and a mixed solvent thereof. It is.
- the compounds of the present invention hand showing excellent affinity for dopamine receptors holiday, affinity for de one dopamine D 2 receptors is low, shows excellent separation properties.
- the compound of the present invention is useful as an agent for preventing and treating diseases such as schizophrenia and cerebrovascular disorders and problematic behavior associated with senile dementia, and as a drug not having the side effect of extrapyramidal disorders. Useful.
- the compound of the present invention is added with conventional bulking agents, binders, disintegrants, pH regulators, solubilizers, etc., and tablets, pills, capsules, It can be prepared into granules, powders, solutions, emulsions, suspensions, injections, etc.
- the compound of the present invention can be orally or parenterally administered to an adult patient in one or several doses of 0.1 to 50011 / day. This dose can be adjusted appropriately according to the type of disease, age, weight, and symptoms of the patient.
- Table B shows the structure and physical properties data of this compound and the compound obtained in the same manner.
- Table A shows the structure and physical properties data of this compound and the compound obtained in the same manner.
- the precipitated crystals were collected and recrystallized three times with ethanol to obtain 75.5 g of crystals.
- the crystals were separated with dichloromethane and a 0.5N aqueous sodium hydroxide solution, and the organic layer was washed successively with a 0.5N aqueous sodium hydroxide solution and saturated saline. After the organic layer was dried over anhydrous sodium sulfate, the desiccant was separated by filtration. 18.6 g of diisoprovirethylamine was added to the filtrate, and 14.6 g of ethyl ethyl carbonate was added dropwise under ice-cooling over 30 minutes.
- the first ripple liquid was concentrated under reduced pressure, and separated with a 0.5N aqueous sodium hydroxide solution using a chloroform solution. Further, the organic layer was washed with a 0.5N aqueous sodium hydroxide solution and saturated. After sequentially washing with a saline solution, the extract was dried over anhydrous potassium carbonate. After the desiccant was filtered off, the filtrate was concentrated under reduced pressure. The obtained residue was dissolved in ethanol and added to an ethanol solution of (1.0) -di-P-toluoyltartaric acid (11.0 g) with stirring.
- (+) 1-ethoxyethoxycarbonyl 3 -— [2- (4-fluorophenyl) -12-year-old oxoethyl] 17.0 g of pyrrolidine were dissolved in 85 ml of acetic acid, and 47% hydrobromic acid was added. 0.85 ml of an aqueous solution was added. Then, 9.73 g of bromine was added dropwise at room temperature over 30 minutes. After stirring the reaction mixture at room temperature for 2 hours, acetic acid was distilled off under reduced pressure.
- Tables A and F show the structure and physical property data of this compound and the compound obtained in the same manner.
- Tables A, B, C, D, E, G and H show the structures and physical property data of this compound and the compound obtained in the same manner.
- Tables D, E, F and H show the structural and physical properties data of this compound and the compound obtained in the same manner. It was shown to.
- the reaction mixture was poured into water, extracted with ethyl acetate and washed with water.
- the organic layer was extracted with 1N hydrochloric acid, the aqueous layer was made alkaline by adding a 10% aqueous solution of sodium hydroxide, and extracted again with ethyl acetate.
- Tables E and F show the structure and physical property data of this compound and the compound obtained in the same manner.
- Table E shows the structure and physical property data of this compound and the compound obtained in the same manner.
- Table I shows the structure and physical properties of this compound and the compound obtained in the same manner.
- Table I shows the structure and physical properties data of this compound.
- Table I shows the structure and physical property data of this compound and the compound obtained in the same manner.
- the conversion of chlorine atoms to iodine atoms was carried out in the same manner as described above, except that the 47% aqueous hydrobromic acid solution was replaced with a 57% aqueous hydroiodic acid solution.
- the free base was obtained by neutralization with an aqueous sodium hydroxide solution or a saturated aqueous sodium hydrogen carbonate solution.
- N-t-Butoxycarbonyl-4-1 (4-fluorobenzoyl) piperidine 1.89 g is dissolved in 1 Om1 of getyl ether, and cooled with water to give a 1 M solution of methylmagnesium iodide in getyl ether 6 ⁇ Added 2mi. After stirring at room temperature for 30 minutes, a saturated aqueous solution of ammonium chloride was added, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with a 5% aqueous hydrogen sulfate solution and saturated saline, and then dried over anhydrous magnesium sulfate. And dried. After the desiccant was filtered off, the solvent was distilled off under reduced pressure.
- Table J shows the structure and physical property data of this compound and the compound obtained in a similar manner.
- lithium diisopropamide was used instead of sodium hydride (including 15-crown-5 ether) as the base, and the reaction temperature was -5 (TC After that, the temperature was raised to room temperature.
- Tables K and L show the structure and physical property data of this compound and the compound obtained in the same manner.
- Table K shows the structure and physical properties data of this compound and the compound obtained in the same manner.
- Table L shows the structures and physical properties of this compound and compounds obtained in the same manner.
- Table B shows the structure and physical property data of this compound.
- Table D shows the structure and physical property data of the compound.
- Example No. f which was used to synthesize the compound.
- CD J-04 13 4-Me O-P h H HC1 178.
- Ne 1 Compound number.
- Human D 4 receptor binding test Human D 4 CHO cell membranes expressing the receptor, the [3 Hl-spiperone (0. 5 nM) and test drug, 5mM EDTA, 1. 5 mM calcium chloride, 5mM chloride force 5_Rei mM Bok squirrel HCl buffer containing Riumu and 12 Omm chloride Natoriumu in (pH7. 4), was reacted for 2 hours at 27 e C.
- the solution was suction-filtered through a glass filter (GFZB), and the radioactivity of the filter paper was measured with a liquid scintillation flask.
- GFZB glass filter
- a suppression curve was obtained by reacting a constant concentration of [ 3 H] spiperone with a test drug at a different concentration under the above conditions, and from this suppression curve, the concentration of the test drug that inhibited [ 3 H] subiperone binding by 50% ( I Cso) and the results are shown in Table M.
- Rat striatal membrane was used as a receptor sample.
- the binding reaction using the [ 3 H] -labeled ligand was performed by the following method described in ol. Pharmacol., 43, 749 (1993).
- Rat striatum was homogenized with 50 mM Tris-HCl buffer (pH 7.4), centrifuged at 48,000 g, and the precipitate was washed once with Tris-HCl buffer. The precipitate was suspended in a 5 OmM Tris-HCl buffer (pH 7.4) containing 120 mM sodium chloride, 5 mM potassium chloride, calcium dichloride and 1 mM magnesium chloride to prepare a membrane sample.
- the compound of the present invention is useful as an agent for preventing and treating diseases such as schizophrenia and cerebrovascular disorders and problematic behavior associated with senile dementia, and as a drug not having the side effect of extrapyramidal disorders. Useful.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU50149/96A AU694626B2 (en) | 1995-03-22 | 1996-03-22 | Thiazole derivatives |
EP96906932A EP0816362A4 (en) | 1995-03-22 | 1996-03-22 | THIAZOLE DERIVATIVES |
JP52788596A JP3884477B2 (ja) | 1995-03-22 | 1996-03-22 | チアゾール誘導体 |
Applications Claiming Priority (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7/62328 | 1995-03-22 | ||
JP7/62326 | 1995-03-22 | ||
JP6232695 | 1995-03-22 | ||
JP7/62327 | 1995-03-22 | ||
JP6232795 | 1995-03-22 | ||
JP7/62329 | 1995-03-22 | ||
JP6232895 | 1995-03-22 | ||
JP6232995 | 1995-03-22 | ||
JP7/287741 | 1995-11-07 | ||
JP28774295 | 1995-11-07 | ||
JP28774495 | 1995-11-07 | ||
JP28774395 | 1995-11-07 | ||
JP7/287744 | 1995-11-07 | ||
JP7/287742 | 1995-11-07 | ||
JP28774195 | 1995-11-07 | ||
JP7/287743 | 1995-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996029330A1 true WO1996029330A1 (fr) | 1996-09-26 |
Family
ID=27572540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/000763 WO1996029330A1 (fr) | 1995-03-22 | 1996-03-22 | Derives de la thiazole |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0816362A4 (ja) |
JP (1) | JP3884477B2 (ja) |
KR (1) | KR19980703192A (ja) |
CN (1) | CN1184478A (ja) |
AU (1) | AU694626B2 (ja) |
CA (1) | CA2215951A1 (ja) |
WO (1) | WO1996029330A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998012195A1 (fr) * | 1996-09-20 | 1998-03-26 | Taisho Pharmaceutical Co., Ltd. | Derives du 2-carbonylthiazole et leur utilisation |
US6946478B2 (en) * | 1999-03-26 | 2005-09-20 | Astrazeneca Ab | Compounds |
US7265227B2 (en) | 2001-07-23 | 2007-09-04 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
US7304077B2 (en) | 2000-09-04 | 2007-12-04 | Astrazeneca Ab | Chemical compounds |
US7348341B2 (en) | 2000-05-31 | 2008-03-25 | Astrazeneca Ab | Chemical compounds |
WO2008156601A1 (en) | 2007-06-14 | 2008-12-24 | Amgen Inc. | Tricyclic inhibitors of hydroxysteroid dehydrogenases |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1065205T3 (da) * | 1998-03-18 | 2003-06-23 | Taisho Pharmaceutical Co Ltd | Heteroaromatiske derivater |
ES2222411T3 (es) * | 1998-03-18 | 2005-02-01 | Taisho Pharmaceutical Co. Ltd | Derivados aromaheterociclicos para utilizacion como antagonistas de receptor d4 de dopamina. |
HN2002000156A (es) | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
US6951849B2 (en) | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
EP1432420B1 (en) * | 2001-10-02 | 2011-07-13 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
WO2011156246A1 (en) * | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
CN104337812B (zh) * | 2013-07-29 | 2018-09-14 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其使用方法和用途 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6212768A (ja) * | 1985-06-22 | 1987-01-21 | サンド・アクチエンゲゼルシヤフト | 新規チアゾ−ル類、その製法および医薬 |
JPS63243079A (ja) * | 1987-03-27 | 1988-10-07 | Sankyo Co Ltd | チアゾ−ル誘導体 |
JPH05345772A (ja) * | 1992-03-06 | 1993-12-27 | Fujisawa Pharmaceut Co Ltd | 新規複素環化合物 |
JPH06500794A (ja) * | 1991-03-28 | 1994-01-27 | エーザイ株式会社 | 複素環式−環式アミン誘導体 |
JPH072850A (ja) * | 1993-03-05 | 1995-01-06 | Adir | 新規(アリール(アルキル)カルボニル)ヘテロ環状 化合物 |
JPH07501075A (ja) * | 1991-11-20 | 1995-02-02 | ワーナー−ランバート・コンパニー | 中枢神経系剤としての1,3−置換シクロアルケンおよびシクロアルカン |
WO1995008533A1 (fr) * | 1993-09-21 | 1995-03-30 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de n-(3-pyrrolidinyl)benzamide |
JPH07188215A (ja) * | 1993-12-28 | 1995-07-25 | Meiji Seika Kaisha Ltd | アゾール誘導体及びその塩 |
JPH07258252A (ja) * | 1994-03-16 | 1995-10-09 | Meiji Seika Kaisha Ltd | チアゾール化合物およびその塩 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3703435A1 (de) * | 1987-02-05 | 1988-08-18 | Thomae Gmbh Dr K | Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE3923675A1 (de) * | 1989-07-18 | 1991-01-24 | Basf Ag | Amonoalkylsubstituierte 2-aminothiazole und diese enthaltende therapeutische mittel |
GB9026257D0 (en) * | 1990-12-03 | 1991-01-16 | Fujisawa Pharmaceutical Co | Thiazole derivatives and their preparation |
JPH04352770A (ja) * | 1991-05-30 | 1992-12-07 | Taisho Pharmaceut Co Ltd | アミノアルキルチアゾール誘導体 |
-
1996
- 1996-03-22 CA CA002215951A patent/CA2215951A1/en not_active Abandoned
- 1996-03-22 WO PCT/JP1996/000763 patent/WO1996029330A1/ja not_active Application Discontinuation
- 1996-03-22 AU AU50149/96A patent/AU694626B2/en not_active Ceased
- 1996-03-22 CN CN96194020A patent/CN1184478A/zh active Pending
- 1996-03-22 KR KR1019970706595A patent/KR19980703192A/ko not_active Application Discontinuation
- 1996-03-22 JP JP52788596A patent/JP3884477B2/ja not_active Expired - Fee Related
- 1996-03-22 EP EP96906932A patent/EP0816362A4/en not_active Withdrawn
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6212768A (ja) * | 1985-06-22 | 1987-01-21 | サンド・アクチエンゲゼルシヤフト | 新規チアゾ−ル類、その製法および医薬 |
JPS63243079A (ja) * | 1987-03-27 | 1988-10-07 | Sankyo Co Ltd | チアゾ−ル誘導体 |
JPH06500794A (ja) * | 1991-03-28 | 1994-01-27 | エーザイ株式会社 | 複素環式−環式アミン誘導体 |
JPH07501075A (ja) * | 1991-11-20 | 1995-02-02 | ワーナー−ランバート・コンパニー | 中枢神経系剤としての1,3−置換シクロアルケンおよびシクロアルカン |
JPH05345772A (ja) * | 1992-03-06 | 1993-12-27 | Fujisawa Pharmaceut Co Ltd | 新規複素環化合物 |
JPH06279413A (ja) * | 1992-03-06 | 1994-10-04 | Fujisawa Pharmaceut Co Ltd | 新規複素環化合物 |
JPH072850A (ja) * | 1993-03-05 | 1995-01-06 | Adir | 新規(アリール(アルキル)カルボニル)ヘテロ環状 化合物 |
WO1995008533A1 (fr) * | 1993-09-21 | 1995-03-30 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de n-(3-pyrrolidinyl)benzamide |
JPH07188215A (ja) * | 1993-12-28 | 1995-07-25 | Meiji Seika Kaisha Ltd | アゾール誘導体及びその塩 |
JPH07258252A (ja) * | 1994-03-16 | 1995-10-09 | Meiji Seika Kaisha Ltd | チアゾール化合物およびその塩 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0816362A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998012195A1 (fr) * | 1996-09-20 | 1998-03-26 | Taisho Pharmaceutical Co., Ltd. | Derives du 2-carbonylthiazole et leur utilisation |
US6166033A (en) * | 1996-09-20 | 2000-12-26 | Taisho Pharmaceutical Co., Ltd. | 2-carbonylthiazole derivatives and use of the same |
CN1088707C (zh) * | 1996-09-20 | 2002-08-07 | 大正制药株式会社 | 2-羰基噻唑衍生物及其用途 |
US6946478B2 (en) * | 1999-03-26 | 2005-09-20 | Astrazeneca Ab | Compounds |
US7348341B2 (en) | 2000-05-31 | 2008-03-25 | Astrazeneca Ab | Chemical compounds |
US7304077B2 (en) | 2000-09-04 | 2007-12-04 | Astrazeneca Ab | Chemical compounds |
US7265227B2 (en) | 2001-07-23 | 2007-09-04 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
WO2008156601A1 (en) | 2007-06-14 | 2008-12-24 | Amgen Inc. | Tricyclic inhibitors of hydroxysteroid dehydrogenases |
US8765788B2 (en) | 2007-06-14 | 2014-07-01 | Amgen Inc. | Tricyclic inhibitors of hydroxysteroid dehydrogenases |
Also Published As
Publication number | Publication date |
---|---|
CA2215951A1 (en) | 1996-09-26 |
KR19980703192A (ko) | 1998-10-15 |
CN1184478A (zh) | 1998-06-10 |
EP0816362A1 (en) | 1998-01-07 |
EP0816362A4 (en) | 1998-07-08 |
AU5014996A (en) | 1996-10-08 |
JP3884477B2 (ja) | 2007-02-21 |
AU694626B2 (en) | 1998-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI82242B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3-(piperidinyl)-1h-indazolderivat. | |
CA2748251C (en) | Bicyclic heterocyclic compound for use as a sensory neuron specific sodium channel inhibitor | |
JP5624762B2 (ja) | 新規ピロリノン誘導体およびそれを含有する医薬組成物 | |
TWI386403B (zh) | 用於治療肥胖及其它中樞神經系統(cns)病症之吡唑化物 | |
JP2007506715A (ja) | ガンマセクレターゼ阻害剤 | |
AU690951B2 (en) | Cyclic amide derivatives as neurokinin A antagonists | |
WO1996029330A1 (fr) | Derives de la thiazole | |
JP2007505075A (ja) | キノリン化合物およびそれを含む医薬組成物 | |
KR20010042001A (ko) | 아릴피페리딘 유도체 및 그의 용도 | |
JP2006519812A (ja) | フェニルスルホン誘導体およびcns障害の治療におけるその使用 | |
JP2000086603A (ja) | 桂皮酸アミド誘導体および3―フェニルプロピオン酸アミド誘導体 | |
EP0144729A1 (en) | 11-Substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines, a process for their preparation and their use in medicaments | |
US4806649A (en) | 3-(piperidinyl)- and 3- (pyrrolidinyl)-1H-indazoles | |
JP4000186B2 (ja) | 芳香族複素環誘導体 | |
US7094777B2 (en) | 5-HT2A receptor ligands | |
US6291467B1 (en) | Heteroaromatic derivatives | |
EP1641756B1 (en) | 4-arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor | |
JP4168350B2 (ja) | アリールピペリジン誘導体 | |
JPH1095770A (ja) | 4−ベンジリデンピペリジン誘導体 | |
US6166033A (en) | 2-carbonylthiazole derivatives and use of the same | |
EP1207159B1 (en) | Aromaheterocyclic derivatives as dopamine D4 receptor antagonists | |
JP4761802B2 (ja) | アミノフェノール化合物の製造法 | |
JPH07215954A (ja) | 新規ベンゾチアジアジン化合物 | |
JP2008050354A (ja) | 1,3−ジヒドロ−2h−インドール−2−オン化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96194020.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR MX US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2215951 Country of ref document: CA Ref document number: 2215951 Country of ref document: CA Kind code of ref document: A Ref document number: 1997 930732 Country of ref document: US Date of ref document: 19970919 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996906932 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970706595 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1996906932 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970706595 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996906932 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019970706595 Country of ref document: KR |